Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 112 (6) , 463-466
Abstract
No abstract availableKeywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 17 references indexed in Scilit:
- Central origin of the antinociceptive action of botulinum toxin type APharmacology Biochemistry and Behavior, 2009
- Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic MigraineHeadache: The Journal of Head and Face Pain, 2007
- Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication OveruseHeadache: The Journal of Head and Face Pain, 2007
- Botox Therapy for Refractory Chronic MigraineHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Regulation of Calcitonin Gene‐Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine TherapyHeadache: The Journal of Head and Face Pain, 2004
- Neurogenic inflammation in the context of migraineMicroscopy Research and Technique, 2001
- Migraine Prophylactic DrugsCephalalgia, 1997
- Migraine: theories of pathogenesisThe Lancet, 1992
- Amitriptyline in migraine prophylaxis: Changes in pattern of attacks during a controlled clinical trialJournal of Neurology, Neurosurgery & Psychiatry, 1973